3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Breast Neoplasms
19
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma, Renal Cell
2
Advanced Cancer
2
Unilateral Breast Neoplasms
1
Thrombocytosis
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Melphalan
4
Irinotecan
4
Filgrastim
4
Cyclophosphamide
4
Busulfan
4
fludarabine
3
Topotecan
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
pegfilgrastim
2
liposomal doxorubicin
2
Thiotepa
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
ribociclib
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
olaparib
1
mocetinostat
1
lexatumumab
1
irinotecan sucrosofate
1
fludarabine phosphate
1
cixutumumab
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
abemaciclib
×
Clear all
NCT02644460
2023-10-26
AflacST1501
Emory University
Phase 1
Completed
53 enrolled